首页> 外国专利> COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TYPE 1 DIABETES USING A BIOLOGIC RESPONSE MODIFIER IN COMBINATION WITH ONE OR MORE ISLET OR BETA CELL REGENERATION OF REPLACEMENT THERAPIES

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TYPE 1 DIABETES USING A BIOLOGIC RESPONSE MODIFIER IN COMBINATION WITH ONE OR MORE ISLET OR BETA CELL REGENERATION OF REPLACEMENT THERAPIES

机译:使用生物反应修饰剂结合一个或更多个胰岛或BETA细胞再生疗法治疗或预防1型糖尿病的组合物和方法

摘要

Methods and pharmaceutical compositions of a unique Biologic Response Modifier (BRM) that does not suppress the immune system, yet provides protection of beta cells in those with type 1 diabetes and those at risk for type 1 diabetes are described. The methods include utilization of BRMs in combination with islet neogenesis therapies, beta regeneration therapies, islet, beta cell or stem cell transplants, or devices housing islets, beta cells or stem cells for treatment and prevention of type 1 patients and related conditions. The compositions and methods provide for beta cell protection from autoimmune attack for prevention or delay in the onset of type 1 diabetes. The BRM may be used in conjunction with immunosuppressive agents. The BRM may also be used in other conditions found among patients with type 1 diabetes and their relatives for whom there is no treatment or current therapy is unsuccessful.
机译:描述了一种独特的生物反应修饰剂(BRM)的方法和药物组合物,该修饰剂不会抑制免疫系统,但能为1型糖尿病患者和处于1型糖尿病风险的患者提供β细胞的保护。该方法包括将BRM与胰岛新生疗法,β再生疗法,胰岛,β细胞或干细胞移植物或容纳胰岛,β细胞或干细胞的装置结合使用,以治疗和预防1型患者和相关病症。所述组合物和方法提供了针对自身免疫攻击的β细胞保护,以预防或延迟1型糖尿病的发作。 BRM可与免疫抑制剂联合使用。 BRM也可用于没有治疗或目前治疗失败的1型糖尿病患者及其亲属中的其他疾病。

著录项

  • 公开/公告号WO2019099368A1

    专利类型

  • 公开/公告日2019-05-23

    原文格式PDF

  • 申请/专利权人 LEVETAN CLARESA;

    申请/专利号WO2018US60705

  • 发明设计人 LEVETAN CLARESA;

    申请日2018-11-13

  • 分类号A61K38/21;C07K14/47;

  • 国家 WO

  • 入库时间 2022-08-21 11:54:39

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号